Bottom line
BBH vs FBDIX: the short answer
BBH (VanEck Biotech ETF) and FBDIX (Franklin Biotechnology Discovery Fund) share a meaningful slice of their top holdings — about 40% by weight.
But FBDIX is far broader, holding 126 positions to 25 for BBH, so beyond the top names it adds exposure BBH doesn't have.
BBH is cheaper at 0.35% vs 1.01% — a difference of $66 a year per $10,000 invested.
Over five years, FBDIX returned +5.0% a year vs +2.7% for BBH.
FBDIX has a front-end sales load of up to 5.5%; the other does not.
Updated Nov 19, 2026
BBH vs FBDIX side by side
| BBH | FBDIX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | VanEck | Franklin Templeton |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.35% | 1.01% |
| Annual cost per $10k | $35 | $101 |
| 10-yr cost on $10k (prospectus) | $443 | $1,728 |
| Max front load | None | 5.5% |
| 12b-1 fee | — | 0.25% |
| 1-yr return | +21.2% | +43.9% |
| 5-yr return (annualized) | +2.7% | +5.0% |
| 10-yr return (annualized) | +4.5% | +6.4% |
| Best quarter | +27.6% | +29.5% |
| Worst quarter | −18.2% | −24.5% |
| Net assets (fund) | $395.6M | $1.2B |
| Number of holdings | 25 | 126 |
| Portfolio turnover | 19% | 38% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | BBH | FBDIX | Difference |
|---|---|---|---|
| 2025 | +21.2% | +52.3% | −31.1% |
| 2024 | −4.4% | +4.0% | −8.4% |
| 2023 | +3.9% | +18.4% | −14.5% |
| 2022 | −15.1% | −12.7% | −2.5% |
| 2021 | +11.8% | −17.7% | +29.5% |
| 2020 | +22.1% | +29.9% | −7.8% |
| 2019 | +25.8% | +34.8% | −9.1% |
| 2018 | −10.2% | −15.7% | +5.5% |
| 2017 | +16.6% | +18.8% | −2.2% |
| 2016 | −15.0% | −17.2% | +2.1% |
Source: Fund prospectus bar charts
Holdings overlap
8 of BBH's top 25 holdings also appear in FBDIX's top 25.
| Holding | BBH | FBDIX |
|---|---|---|
| Amgen Inc | 15.25% | 4.39% |
| Gilead Sciences Inc | 12.79% | 3.86% |
| Vertex Pharmaceuticals Inc | 9.10% | 3.54% |
| Regeneron Pharmaceuticals Inc | 6.21% | 3.77% |
| Revolution Medicines Inc | 5.27% | 3.01% |
| Argenx SE | 4.97% | 3.62% |
| Insmed Inc | 2.67% | 1.99% |
| Neurocrine Biosciences Inc | 2.08% | 1.82% |
Source: SEC Form N-PORT
BBH top 10
- Amgen Inc — 15.25%
- Gilead Sciences Inc — 12.79%
- Vertex Pharmaceuticals Inc — 9.10%
- Regeneron Pharmaceuticals Inc — 6.21%
- Revolution Medicines Inc — 5.27%
- Argenx SE — 4.97%
- Natera Inc — 4.92%
- IQVIA Holdings Inc — 4.31%
- Alnylam Pharmaceuticals Inc — 3.83%
- Biogen Inc — 3.63%
FBDIX top 10
- Jazz Pharmaceuticals plc — 5.66%
- Amgen, Inc. — 4.39%
- Gilead Sciences, Inc. — 3.86%
- Regeneron Pharmaceuticals, Inc. — 3.77%
- Argenx SE — 3.62%
- Vertex Pharmaceuticals, Inc. — 3.54%
- Franklin Institutional U.S. Government Money Market Fund — 3.18%
- Revolution Medicines, Inc. — 3.01%
- Guardant Health, Inc. — 2.76%
- Ascendis Pharma A/S — 2.56%
FAQ
What is the difference between BBH and FBDIX?
Which is cheaper, BBH or FBDIX?
Should I own both BBH and FBDIX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.